Recombinant Human IL-29/IFN-lambda 1
Interleukin-29(IL-29/IFN-lambda 1), IL-28A and IL-28B, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and the type I IFN family (15-19% aa sequence identity) [1-3]. The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF -9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory region of the target genes. Human IL-29 cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 19 aa signal peptide and a 181 aa mature protein, which is a monomer in solution. It shares 67% and 69% aa sequence identity with human IL-28A and IL-28B, respectively.
Reference
[1]. Vilcek, J. (2003) Nature Immunol. 4:8.
[2]. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
[3]. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
Accession # |
Q8IU54 |
Alternate Names |
Human IL29; IFNL1; IFN-lambda 1; IFN-lambda-1; IL29; IL-29; interferon lambda-1 |
Source |
Human embryonic kidney cell, HEK293-derived human IL-29/IFN-lambda 1 protein |
Protein sequence |
Gly20-Thr200 |
M.Wt |
20.0 kDa |
Appearance |
Solution protein. |
Stability & Storage |
Avoid repeated freeze-thaw cycles. It is recommended that the protein be aliquoted for optimal storage. 12 months from date of receipt, -20 to -70 °C as supplied. |
Concentration |
0. 2 mg/mL |
Formulation |
Dissolved in sterile PBS buffer. |
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers. |
Biological Activity |
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. The EC50 for this effect is 1-5 ng/mL. |
Shipping Condition |
Shipping with dry ice. |
Handling |
Centrifuge the vial prior to opening. |
Usage |
For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 95%, determined by SDS-PAGE.
- Datasheet
Endotoxin: <0.010 EU per 1 ug of the protein by the LAL method.